(Q37772320)

22 August 2017

1 reference

title

The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects (English)

1 reference

22 August 2017

Laura Marconato

1

1 reference

22 August 2017

publication date

1 April 2011

1 reference

22 August 2017

published in

The Veterinary Journal

1 reference

22 August 2017

volume

188

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

34-38

1 reference

Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Acute tumor lysis syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Hematologic changes associated with half-body irradiation in dogs with lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Therapeutic vaccines for non-Hodgkin B-cell lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Hematopoietic stem-cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Chemoimmunotherapy for canine lymphosarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Detection of minimal residual disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Utility of FDG-PET scanning in lymphoma by WHO classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Dacarbazine as single-agent therapy for relapsed lymphoma in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

A preliminary assessment of whole-body radiotherapy interposed within a chemotherapy protocol for canine lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

On the association between canine malignant lymphoma and opportunity for exposure to 2,4-dichlorophenoxyacetic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

PET/CT for therapy response assessment in lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Detection of neoplastic lymphocytes in peripheral blood of dogs with lymphoma by polymerase chain reaction for antigen receptor gene rearrangement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Purine analogues in advanced T-cell lymphoid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Association between waste management and cancer in companion animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Actinomycin D for reinduction of remission in dogs with resistant lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Treatment of refractory T-cell malignancies using gemcitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Human disease characterization: real-time quantitative PCR analysis of gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Spontaneously occurring tumors of companion animals as models for human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Paraneoplastic disorders in dogs with hematopoietic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Chemotherapy followed by half-body radiation therapy for canine lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Ten years of rituximab in NHL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2010.04.027

10.1016/J.TVJL.2010.04.027

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference